Synergistic anticancer activity of triptolide combined with cisplatin enhances apoptosis in gastric cancer in vitro and in vivo
Abstract Cisplatin is an anticancer agent that is effective against several types of cancer, including gastric cancer. However, its therapeutic application is limited by its toxicity in normal tissues and complications caused in patients. In this study, we attempted to clarify how triptolide, an act...
Saved in:
Published in | Cancer letters Vol. 319; no. 2; pp. 203 - 213 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Ireland
Elsevier Limited
28.06.2012
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract Cisplatin is an anticancer agent that is effective against several types of cancer, including gastric cancer. However, its therapeutic application is limited by its toxicity in normal tissues and complications caused in patients. In this study, we attempted to clarify how triptolide, an active component extracted from the traditional Chinese herbal medicine Tripterygium wilfordii Hook F (TWHF), enhances cisplatin-induced cytotoxicity in gastric cancer SC-M1 cells. After low-dose combined treatments with triptolide and cisplatin, a decrease in viability with a concomitant increase in apoptosis was observed in SC-M1 cells but not in normal cells. Apoptosis induced by the combined treatments was accompanied by loss of mitochondrial membrane potential and release of cytochrome c . Triptolide increased the cisplatin-induced activation of caspase-3 and caspase-9 and the downstream cleavage of PARP in SC-M1 cells. Results of these in vitro experiments indicated that triptolide enhanced cytotoxicity in cisplatin-treated SC-M1 cells and that this effect is mediated by apoptosis through a mitochondrial pathway. Furthermore, using a SCID mouse xenograft model, we demonstrated that the combined treatment completely suppressed tumor growth via down-regulation of proliferating cell nuclear antigen expression without significant side effects. These results suggest that lower concentrations of cisplatin and triptolide used in combination may produce a synergistic anticancer effect that warrants further investigation for its potential clinical applications. |
---|---|
AbstractList | Cisplatin is an anticancer agent that is effective against several types of cancer, including gastric cancer. However, its therapeutic application is limited by its toxicity in normal tissues and complications caused in patients. In this study, we attempted to clarify how triptolide, an active component extracted from the traditional Chinese herbal medicine Tripterygium wilfordii Hook F (TWHF), enhances cisplatin-induced cytotoxicity in gastric cancer SC-M1 cells. After low-dose combined treatments with triptolide and cisplatin, a decrease in viability with a concomitant increase in apoptosis was observed in SC-M1 cells but not in normal cells. Apoptosis induced by the combined treatments was accompanied by loss of mitochondrial membrane potential and release of cytochrome c. Triptolide increased the cisplatin-induced activation of caspase-3 and caspase-9 and the downstream cleavage of PARP in SC-M1 cells. Results of these in vitro experiments indicated that triptolide enhanced cytotoxicity in cisplatin-treated SC-M1 cells and that this effect is mediated by apoptosis through a mitochondrial pathway. Furthermore, using a SCID mouse xenograft model, we demonstrated that the combined treatment completely suppressed tumor growth via down-regulation of proliferating cell nuclear antigen expression without significant side effects. These results suggest that lower concentrations of cisplatin and triptolide used in combination may produce a synergistic anticancer effect that warrants further investigation for its potential clinical applications. Cisplatin is an anticancer agent that is effective against several types of cancer, including gastric cancer. However, its therapeutic application is limited by its toxicity in normal tissues and complications caused in patients. In this study, we attempted to clarify how triptolide, an active component extracted from the traditional Chinese herbal medicineTripterygium wilfordiiHook F (TWHF), enhances cisplatin-induced cytotoxicity in gastric cancer SC-M1 cells. After low-dose combined treatments with triptolide and cisplatin, a decrease in viability with a concomitant increase in apoptosis was observed in SC-M1 cells but not in normal cells. Apoptosis induced by the combined treatments was accompanied by loss of mitochondrial membrane potential and release of cytochromec. Triptolide increased the cisplatin-induced activation of caspase-3 and caspase-9 and the downstream cleavage of PARP in SC-M1 cells. Results of thesein vitroexperiments indicated that triptolide enhanced cytotoxicity in cisplatin-treated SC-M1 cells and that this effect is mediated by apoptosis through a mitochondrial pathway. Furthermore, using a SCID mouse xenograft model, we demonstrated that the combined treatment completely suppressed tumor growth via down-regulation of proliferating cell nuclear antigen expression without significant side effects. These results suggest that lower concentrations of cisplatin and triptolide used in combination may produce a synergistic anticancer effect that warrants further investigation for its potential clinical applications. Abstract Cisplatin is an anticancer agent that is effective against several types of cancer, including gastric cancer. However, its therapeutic application is limited by its toxicity in normal tissues and complications caused in patients. In this study, we attempted to clarify how triptolide, an active component extracted from the traditional Chinese herbal medicine Tripterygium wilfordii Hook F (TWHF), enhances cisplatin-induced cytotoxicity in gastric cancer SC-M1 cells. After low-dose combined treatments with triptolide and cisplatin, a decrease in viability with a concomitant increase in apoptosis was observed in SC-M1 cells but not in normal cells. Apoptosis induced by the combined treatments was accompanied by loss of mitochondrial membrane potential and release of cytochrome c . Triptolide increased the cisplatin-induced activation of caspase-3 and caspase-9 and the downstream cleavage of PARP in SC-M1 cells. Results of these in vitro experiments indicated that triptolide enhanced cytotoxicity in cisplatin-treated SC-M1 cells and that this effect is mediated by apoptosis through a mitochondrial pathway. Furthermore, using a SCID mouse xenograft model, we demonstrated that the combined treatment completely suppressed tumor growth via down-regulation of proliferating cell nuclear antigen expression without significant side effects. These results suggest that lower concentrations of cisplatin and triptolide used in combination may produce a synergistic anticancer effect that warrants further investigation for its potential clinical applications. |
Author | Yeh, Jih-I Li, Chia-Jung Wang, Ming-Hseng Sheu, Lai-Fa Chu, Ching-Yu Huang, Lin-Huang Hsu, Hsue-Yin |
Author_xml | – sequence: 1 fullname: Li, Chia-Jung – sequence: 2 fullname: Chu, Ching-Yu – sequence: 3 fullname: Huang, Lin-Huang – sequence: 4 fullname: Wang, Ming-Hseng – sequence: 5 fullname: Sheu, Lai-Fa – sequence: 6 fullname: Yeh, Jih-I – sequence: 7 fullname: Hsu, Hsue-Yin |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22306340$$D View this record in MEDLINE/PubMed |
BookMark | eNpdkV-L1DAUxYOsuLOr30Ak4IsvrTdJk2ZeBFnWP7Dgw-pzSNN0N2MnqUlnZJ786t7SUcGXhBzOOfeS3xW5iCl6Ql4yqBkw9XZXOxtHP9ccGK-B1QDqCdkw3fKq3Wq4IBsQ0FRCC3lJrkrZAYBsWvmMXHIuQIkGNuTX_Sn6_BDKHBy1EU8bnc_Uujkcw3yiaaBzDtOcxtB76tK-C9H39GeYH6kLZRrtHCL18XHJFWqnhN4SCkX1wRbMOnruRAUrc8I5_fo4pufk6WDH4l-c72vy7cPt15tP1d2Xj59v3t9VruFirrq-9VvXKOkkBy1w_6FT3Kmhlaq13dZJUH3fWSEtg75FTWgt2wGkaLRmUlyTN2vvlNOPgy-z2Yfi_Dja6NOhGMaFZiC13KL19X_WXTrkiNsZhmOgVbBt0NWsLpdTKdkPZsphb_PJMDALILMzKyCzADLADALC2Ktz-aHb-_5v6A8RNLxbDR5_4xh8Nm4MEbGM3_3Jl3-rmIKl5n5hvCBmHPEKpsRvtoallA |
CitedBy_id | crossref_primary_10_1038_srep32779 crossref_primary_10_3892_ol_2016_4379 crossref_primary_10_1002_cmdc_201800343 crossref_primary_10_1016_j_bcp_2019_07_008 crossref_primary_10_1007_s12010_018_2869_1 crossref_primary_10_3389_fonc_2022_834072 crossref_primary_10_1016_j_cbi_2014_01_008 crossref_primary_10_1186_s12951_020_00681_8 crossref_primary_10_3109_0886022X_2015_1096730 crossref_primary_10_3892_mmr_2013_1851 crossref_primary_10_1016_j_ejphar_2016_02_035 crossref_primary_10_1016_j_biopha_2018_12_010 crossref_primary_10_1016_j_bbrc_2018_09_105 crossref_primary_10_1021_acs_chemrestox_5b00153 crossref_primary_10_1016_j_ejmech_2014_02_039 crossref_primary_10_20307_nps_2019_25_4_311 crossref_primary_10_1038_s41598_020_77401_7 crossref_primary_10_1016_j_actbio_2019_03_022 crossref_primary_10_1038_srep07647 crossref_primary_10_1016_j_jep_2018_05_039 crossref_primary_10_1088_1757_899X_1011_1_012015 crossref_primary_10_1016_j_taap_2012_07_022 crossref_primary_10_1142_S0192415X14500323 crossref_primary_10_18632_oncotarget_5411 crossref_primary_10_1007_s11605_015_3000_3 crossref_primary_10_1016_j_jconrel_2018_11_013 crossref_primary_10_1021_acsnano_8b08246 crossref_primary_10_1016_j_biopha_2020_111044 crossref_primary_10_1111_febs_13532 crossref_primary_10_1016_j_canlet_2022_215591 crossref_primary_10_3727_096504013X13657689382932 crossref_primary_10_1016_j_toxlet_2014_08_017 crossref_primary_10_14712_fb2015061050195 crossref_primary_10_3390_ijms20225559 crossref_primary_10_1186_1471_2407_14_271 crossref_primary_10_3892_ijo_2013_1843 crossref_primary_10_18632_oncotarget_19554 crossref_primary_10_1007_s13197_017_3014_9 crossref_primary_10_1038_aps_2017_95 crossref_primary_10_3389_fimmu_2022_1070367 crossref_primary_10_7314_APJCP_2015_16_11_4571 crossref_primary_10_1016_j_biopha_2018_05_088 crossref_primary_10_6000_1929_2279_2013_02_02_6 crossref_primary_10_1016_j_jep_2014_01_026 crossref_primary_10_1016_j_apsb_2023_12_008 crossref_primary_10_1021_acsomega_3c03337 crossref_primary_10_1021_acs_chemmater_6b05095 crossref_primary_10_1016_j_canlet_2024_216622 crossref_primary_10_1016_j_lfs_2021_119802 crossref_primary_10_3389_fphar_2023_1157433 crossref_primary_10_3892_ijmm_2013_1574 crossref_primary_10_1016_j_addr_2022_114445 crossref_primary_10_1080_13880209_2016_1199045 crossref_primary_10_1080_14786419_2013_871547 crossref_primary_10_3390_biomedicines9060586 crossref_primary_10_1016_j_bbcan_2023_188998 crossref_primary_10_1016_j_biopha_2019_109118 crossref_primary_10_1016_j_biopha_2017_06_041 crossref_primary_10_3892_etm_2021_10605 crossref_primary_10_3390_biom8040163 crossref_primary_10_3390_molecules17089348 crossref_primary_10_1002_smll_201702446 crossref_primary_10_1016_j_cbi_2014_01_010 crossref_primary_10_1186_s40364_015_0043_2 crossref_primary_10_1039_C7NR03016A crossref_primary_10_3892_mmr_2019_10296 crossref_primary_10_1016_j_jcis_2016_06_071 crossref_primary_10_1016_j_phrs_2020_105377 crossref_primary_10_3389_fphar_2018_00104 |
Cites_doi | 10.3109/10428190109064582 10.1002/ijc.25294 10.1016/j.intimp.2011.01.012 10.1159/000112419 10.1002/j.1939-4640.2000.tb02137.x 10.3892/mmr_00000284 10.1136/pgmj.2006.055426 10.1038/nprot.2006.5 10.1016/j.toxlet.2009.10.028 10.1016/j.canlet.2009.10.013 10.1182/blood-2010-11-314708 10.1002/art.10411 10.1182/blood-2005-09-3898 10.1038/sj.onc.1204981 10.1056/NEJMe068121 10.1021/ja00775a078 10.1038/nprot.2006.478 10.1074/jbc.M512044200 10.1097/CAD.0b013e3280146296 10.1124/pr.58.3.10 10.1530/REP-08-0422 10.3748/wjg.v12.i3.354 10.1016/0065-2571(84)90007-4 10.1007/s00432-009-0583-7 10.1517/phgs.5.3.225.29829 10.1016/S0304-3835(98)00222-5 |
ContentType | Journal Article |
Copyright | Elsevier Ireland Ltd Copyright © 2012 Elsevier Ireland Ltd. All rights reserved. Copyright Elsevier Limited Jun 28, 2012 |
Copyright_xml | – notice: Elsevier Ireland Ltd – notice: Copyright © 2012 Elsevier Ireland Ltd. All rights reserved. – notice: Copyright Elsevier Limited Jun 28, 2012 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TO 7U9 H94 K9. NAPCQ 7QO 8FD FR3 P64 |
DOI | 10.1016/j.canlet.2012.01.006 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Biotechnology Research Abstracts Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Engineering Research Database Biotechnology Research Abstracts Technology Research Database Biotechnology and BioEngineering Abstracts |
DatabaseTitleList | MEDLINE AIDS and Cancer Research Abstracts Engineering Research Database |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1872-7980 |
EndPage | 213 |
ExternalDocumentID | 3242243051 10_1016_j_canlet_2012_01_006 22306340 1_s2_0_S0304383512000316 |
Genre | Journal Article |
GroupedDBID | - 08R 0R 1 1- 1B1 1P 1RT 1~. 1~5 29B 3O- 3V. 4.4 457 4CK 4G. 53G 55 5GY 5RE 5VS 6J9 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P 9JM AABNK AACTN AAEDT AAIAV AAIKJ AAKOC AALMO AALRI AAOAW AAPBV AAQFI AAQXK AAWTL AAXUO ABBQC ABFLS ABFNM ABFRF ABGSF ABLVK ABMAC ABMZM ABPIF ABPTK ABQIS ABUDA ABUWG ABWYI ABXDB ABYKQ ACDAQ ACGFO ACGFS ACIUM ACPRK ACRLP ADALY ADBBV ADEZE ADFRT ADUVX AEBSH AEFWE AEHWI AEKER AENEX AEVXI AFCTW AFFNX AFKRA AFKWA AFRAH AFRHN AFTJW AFXIZ AGHFR AGRDE AGUBO AGYEJ AHHHB AHMBA AI. AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AZFZN AZQEC BBAFP BBNVY BENPR BHPHI BKEYQ BKOJK BLXMC BNPGV BPHCQ BVXVI CS3 DOVZS DU5 DWQXO EBS EFJIC EJD EO8 EO9 EP2 EP3 F3I F5P FDB FEDTE FGOYB FIRID FNPLU FO FYUFA G- G-2 G-Q GBLVA GJ GNUQQ GUQSH HCIFZ HED HMK HMO HVGLF HZ IH2 IHE IPNFZ J1W K K-O KOM LCYCR LK8 M M1P M29 M2M M2O M41 M7P MO0 N9A NAPCQ O-L O9- OAUVE OC OO- OZT P-8 P-9 P2P PADUT PC. PQEST PQQKQ PQUKI PRINS PROAC PSQYO Q38 R2- RIG ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSU SSZ T5K UDS VH1 WUQ X7M XFK Z5R ZGI --- --K --M .1- .FO .~1 0R~ 1P~ 8P~ AAEDW AAXKI ABJNI ADMUD AKRWK AXJTR CGR CUY CVF ECM EIF FYGXN HZ~ NPM OC~ ~G- .55 .GJ AAYXX AFJKZ CITATION 7TO 7U9 H94 K9. 7QO 8FD FR3 P64 |
ID | FETCH-LOGICAL-c423t-bd7e9c465c52083223fb62c6f7567ab9c506ddba35a10d767a38857f053488153 |
ISSN | 0304-3835 |
IngestDate | Fri Aug 16 08:58:16 EDT 2024 Thu Oct 10 16:18:11 EDT 2024 Thu Sep 26 16:50:52 EDT 2024 Sat Sep 28 07:57:50 EDT 2024 Thu Aug 18 17:14:28 EDT 2022 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Xenograft Synergism Mitochondrial apoptotic pathway Triptolide Cisplatin |
Language | English |
License | Copyright © 2012 Elsevier Ireland Ltd. All rights reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c423t-bd7e9c465c52083223fb62c6f7567ab9c506ddba35a10d767a38857f053488153 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
PMID | 22306340 |
PQID | 1506076094 |
PQPubID | 2031080 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_1238105859 proquest_journals_1506076094 crossref_primary_10_1016_j_canlet_2012_01_006 pubmed_primary_22306340 elsevier_clinicalkeyesjournals_1_s2_0_S0304383512000316 |
PublicationCentury | 2000 |
PublicationDate | 2012-06-28 |
PublicationDateYYYYMMDD | 2012-06-28 |
PublicationDate_xml | – month: 06 year: 2012 text: 2012-06-28 day: 28 |
PublicationDecade | 2010 |
PublicationPlace | Ireland |
PublicationPlace_xml | – name: Ireland – name: Clare |
PublicationTitle | Cancer letters |
PublicationTitleAlternate | Cancer Lett |
PublicationYear | 2012 |
Publisher | Elsevier Limited |
Publisher_xml | – name: Elsevier Limited |
References | Huynh (10.1016/j.canlet.2012.01.006_b0095) 2000; 21 Tao (10.1016/j.canlet.2012.01.006_b0050) 2002; 46 Arkenau (10.1016/j.canlet.2012.01.006_b0015) 2009; 135 Westfall (10.1016/j.canlet.2012.01.006_b0085) 2008; 54 Friedberg (10.1016/j.canlet.2012.01.006_b0170) 2011; 117 Macdonald (10.1016/j.canlet.2012.01.006_b0020) 2006; 355 Sheu (10.1016/j.canlet.2012.01.006_b0120) 1998; 152 Varadhachary (10.1016/j.canlet.2012.01.006_b0005) 2005; 3 Yunos (10.1016/j.canlet.2012.01.006_b0150) 2011; 31 Crew (10.1016/j.canlet.2012.01.006_b0010) 2006; 12 Tengchaisri (10.1016/j.canlet.2012.01.006_b0070) 1998; 133 Chen (10.1016/j.canlet.2012.01.006_b0040) 2001; 42 Ye (10.1016/j.canlet.2012.01.006_b0100) 2010; 192 Kim (10.1016/j.canlet.2012.01.006_b0105) 2010; 30 Sohma (10.1016/j.canlet.2012.01.006_b0110) 2011; 8 Takai (10.1016/j.canlet.2012.01.006_b0145) 2010; 3 Chou (10.1016/j.canlet.2012.01.006_b0125) 1984; 22 Carter (10.1016/j.canlet.2012.01.006_b0155) 2006; 108 Wu (10.1016/j.canlet.2012.01.006_b0165) 2011; 25 Chou (10.1016/j.canlet.2012.01.006_b0175) 2006; 58 Xu (10.1016/j.canlet.2012.01.006_b0090) 2010; 291 Huang (10.1016/j.canlet.2012.01.006_b0140) 2009; 137 Yang (10.1016/j.canlet.2012.01.006_b0075) 2003; 2 Westerheide (10.1016/j.canlet.2012.01.006_b0160) 2006; 281 Tang (10.1016/j.canlet.2012.01.006_b0080) 2007; 83 Olive (10.1016/j.canlet.2012.01.006_b0130) 2006; 1 Kupchan (10.1016/j.canlet.2012.01.006_b0060) 1972; 94 Wang (10.1016/j.canlet.2012.01.006_b0035) 2010; 127 Jiang (10.1016/j.canlet.2012.01.006_b0055) 2001; 20 Sikora (10.1016/j.canlet.2012.01.006_b0030) 2004; 5 Zhang (10.1016/j.canlet.2012.01.006_b0025) 2007; 18 Frezza (10.1016/j.canlet.2012.01.006_b0135) 2007; 2 Matta (10.1016/j.canlet.2012.01.006_b0045) 2009; 1 Liu (10.1016/j.canlet.2012.01.006_b0065) 2011; 11 Fidler (10.1016/j.canlet.2012.01.006_b0115) 2003; 2 |
References_xml | – volume: 42 start-page: 253 year: 2001 ident: 10.1016/j.canlet.2012.01.006_b0040 article-title: Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F publication-title: Leuk. Lymphoma doi: 10.3109/10428190109064582 contributor: fullname: Chen – volume: 2 start-page: 65 year: 2003 ident: 10.1016/j.canlet.2012.01.006_b0075 article-title: Triptolide inhibits the growth and metastasis of solid tumors publication-title: Mol. Cancer Ther. contributor: fullname: Yang – volume: 127 start-page: 2841 year: 2010 ident: 10.1016/j.canlet.2012.01.006_b0035 article-title: A metabonomic approach to chemosensitivity prediction of cisplatin plus 5-fluorouracil in a human xenograft model of gastric cancer publication-title: Int. J. Cancer doi: 10.1002/ijc.25294 contributor: fullname: Wang – volume: 11 start-page: 377 year: 2011 ident: 10.1016/j.canlet.2012.01.006_b0065 article-title: Triptolide and its expanding multiple pharmacological functions publication-title: Int. Immunopharmacol. doi: 10.1016/j.intimp.2011.01.012 contributor: fullname: Liu – volume: 54 start-page: 67 year: 2008 ident: 10.1016/j.canlet.2012.01.006_b0085 article-title: Role of triptolide as an adjunct chemotherapy for ovarian cancer publication-title: Chemotherapy doi: 10.1159/000112419 contributor: fullname: Westfall – volume: 21 start-page: 689 year: 2000 ident: 10.1016/j.canlet.2012.01.006_b0095 article-title: Long-term effects of triptolide on spermatogenesis, epididymal sperm function, and fertility in male rats publication-title: J. Androl. doi: 10.1002/j.1939-4640.2000.tb02137.x contributor: fullname: Huynh – volume: 3 start-page: 479 year: 2010 ident: 10.1016/j.canlet.2012.01.006_b0145 article-title: Synergistic anti-neoplastic effect of AG1478 in combination with cisplatin or paclitaxel on human endometrial and ovarian cancer cells publication-title: Mol. Med. Report doi: 10.3892/mmr_00000284 contributor: fullname: Takai – volume: 3 start-page: 118 year: 2005 ident: 10.1016/j.canlet.2012.01.006_b0005 article-title: Gastric cancer publication-title: Clin. Adv. Hematol. Oncol. contributor: fullname: Varadhachary – volume: 83 start-page: 338 year: 2007 ident: 10.1016/j.canlet.2012.01.006_b0080 article-title: Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma publication-title: Postgrad. Med. J. doi: 10.1136/pgmj.2006.055426 contributor: fullname: Tang – volume: 1 start-page: 23 year: 2006 ident: 10.1016/j.canlet.2012.01.006_b0130 article-title: The comet assay: a method to measure DNA damage in individual cells publication-title: Nat. Protoc. doi: 10.1038/nprot.2006.5 contributor: fullname: Olive – volume: 192 start-page: 212 year: 2010 ident: 10.1016/j.canlet.2012.01.006_b0100 article-title: Effects of cytochrome P4503A inducer dexamethasone on the metabolism and toxicity of triptolide in rat publication-title: Toxicol. Lett. doi: 10.1016/j.toxlet.2009.10.028 contributor: fullname: Ye – volume: 291 start-page: 200 year: 2010 ident: 10.1016/j.canlet.2012.01.006_b0090 article-title: Triptolide simultaneously induces reactive oxygen species, inhibits NF-kappaB activity and sensitizes 5-fluorouracil in colorectal cancer cell lines publication-title: Cancer Lett. doi: 10.1016/j.canlet.2009.10.013 contributor: fullname: Xu – volume: 25 start-page: 551 year: 2011 ident: 10.1016/j.canlet.2012.01.006_b0165 article-title: Triptolide induces apoptosis in human adrenal cancer NCI-H295 cells through a mitochondrial-dependent pathway publication-title: Oncol. Rep. contributor: fullname: Wu – volume: 117 start-page: 2807 year: 2011 ident: 10.1016/j.canlet.2012.01.006_b0170 article-title: The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma publication-title: Blood doi: 10.1182/blood-2010-11-314708 contributor: fullname: Friedberg – volume: 1 start-page: 267 year: 2009 ident: 10.1016/j.canlet.2012.01.006_b0045 article-title: Triptolide induces anti-inflammatory cellular responses publication-title: Am. J. Transl. Res. contributor: fullname: Matta – volume: 8 start-page: 39 year: 2011 ident: 10.1016/j.canlet.2012.01.006_b0110 article-title: Parthenolide, an NF-kappaB inhibitor, suppresses tumor growth and enhances response to chemotherapy in gastric cancer publication-title: Cancer Genomics Proteomics contributor: fullname: Sohma – volume: 46 start-page: 1735 year: 2002 ident: 10.1016/j.canlet.2012.01.006_b0050 article-title: Benefit of an extract of Tripterygium Wilfordii Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study publication-title: Arthritis Rheum. doi: 10.1002/art.10411 contributor: fullname: Tao – volume: 108 start-page: 630 year: 2006 ident: 10.1016/j.canlet.2012.01.006_b0155 article-title: Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells publication-title: Blood doi: 10.1182/blood-2005-09-3898 contributor: fullname: Carter – volume: 20 start-page: 8009 year: 2001 ident: 10.1016/j.canlet.2012.01.006_b0055 article-title: Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells publication-title: Oncogene doi: 10.1038/sj.onc.1204981 contributor: fullname: Jiang – volume: 31 start-page: 1131 year: 2011 ident: 10.1016/j.canlet.2012.01.006_b0150 article-title: Synergism from Sequenced Combinations of Curcumin and Epigallocatechin-3-gallate with Cisplatin in the Killing of Human Ovarian Cancer Cells publication-title: Anticancer Res. contributor: fullname: Yunos – volume: 355 start-page: 76 year: 2006 ident: 10.1016/j.canlet.2012.01.006_b0020 article-title: Gastric cancer–new therapeutic options publication-title: N. Engl. J. Med. doi: 10.1056/NEJMe068121 contributor: fullname: Macdonald – volume: 30 start-page: 5245 year: 2010 ident: 10.1016/j.canlet.2012.01.006_b0105 article-title: Combination chemotherapy with S-1 and platinum in advanced hepatocellular carcinoma publication-title: Anticancer Res. contributor: fullname: Kim – volume: 152 start-page: 63 year: 1998 ident: 10.1016/j.canlet.2012.01.006_b0120 article-title: Epstein-Barr virus LMP1 modulates the malignant potential of gastric carcinoma cells involving apoptosis publication-title: Am. J. Pathol. contributor: fullname: Sheu – volume: 94 start-page: 7194 year: 1972 ident: 10.1016/j.canlet.2012.01.006_b0060 article-title: Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii publication-title: J. Am. Chem. Soc. doi: 10.1021/ja00775a078 contributor: fullname: Kupchan – volume: 2 start-page: 287 year: 2007 ident: 10.1016/j.canlet.2012.01.006_b0135 article-title: Organelle isolation: functional mitochondria from mouse liver, muscle and cultured fibroblasts publication-title: Nat. Protoc. doi: 10.1038/nprot.2006.478 contributor: fullname: Frezza – volume: 281 start-page: 9616 year: 2006 ident: 10.1016/j.canlet.2012.01.006_b0160 article-title: Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death publication-title: J. Biol. Chem. doi: 10.1074/jbc.M512044200 contributor: fullname: Westerheide – volume: 18 start-page: 581 year: 2007 ident: 10.1016/j.canlet.2012.01.006_b0025 article-title: Phase II study of epirubicin plus oxaliplatin and infusional 5-fluorouracil as first-line combination therapy in patients with metastatic or advanced gastric cancer publication-title: Anticancer Drugs. doi: 10.1097/CAD.0b013e3280146296 contributor: fullname: Zhang – volume: 58 start-page: 621 year: 2006 ident: 10.1016/j.canlet.2012.01.006_b0175 article-title: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies publication-title: Pharmacol. Rev. doi: 10.1124/pr.58.3.10 contributor: fullname: Chou – volume: 137 start-page: 449 year: 2009 ident: 10.1016/j.canlet.2012.01.006_b0140 article-title: Expression and in vitro regulation of pituitary adenylate cyclase-activating polypeptide (pacap38) and its type I receptor (pac1-r) in the gonads of tilapia (Oreochromis mossambicus) publication-title: Reproduction doi: 10.1530/REP-08-0422 contributor: fullname: Huang – volume: 12 start-page: 354 year: 2006 ident: 10.1016/j.canlet.2012.01.006_b0010 article-title: Epidemiology of gastric cancer publication-title: World J. Gastroenterol. doi: 10.3748/wjg.v12.i3.354 contributor: fullname: Crew – volume: 22 start-page: 27 year: 1984 ident: 10.1016/j.canlet.2012.01.006_b0125 article-title: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors publication-title: Adv. Enzyme. Regul. doi: 10.1016/0065-2571(84)90007-4 contributor: fullname: Chou – volume: 2 start-page: 855 year: 2003 ident: 10.1016/j.canlet.2012.01.006_b0115 article-title: PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy publication-title: Mol. Cancer Ther. contributor: fullname: Fidler – volume: 135 start-page: 855 year: 2009 ident: 10.1016/j.canlet.2012.01.006_b0015 article-title: Gastric cancer in the era of molecularly targeted agents: current drug development strategies publication-title: J. Cancer Res. Clin. Oncol. doi: 10.1007/s00432-009-0583-7 contributor: fullname: Arkenau – volume: 5 start-page: 225 year: 2004 ident: 10.1016/j.canlet.2012.01.006_b0030 article-title: Personalized cancer therapy–the key to the future publication-title: Pharmacogenomics doi: 10.1517/phgs.5.3.225.29829 contributor: fullname: Sikora – volume: 133 start-page: 169 year: 1998 ident: 10.1016/j.canlet.2012.01.006_b0070 article-title: Antitumor activity of triptolide against cholangiocarcinoma growth in vitro and in hamsters publication-title: Cancer Lett. doi: 10.1016/S0304-3835(98)00222-5 contributor: fullname: Tengchaisri |
SSID | ssj0005475 |
Score | 2.411301 |
Snippet | Abstract Cisplatin is an anticancer agent that is effective against several types of cancer, including gastric cancer. However, its therapeutic application is... Cisplatin is an anticancer agent that is effective against several types of cancer, including gastric cancer. However, its therapeutic application is limited... |
SourceID | proquest crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 203 |
SubjectTerms | Animal models Animals Antineoplastic Combined Chemotherapy Protocols - therapeutic use Antitumor activity Apoptosis Apoptosis - drug effects Cancer therapies Caspase-3 Cell culture Cell growth Cell Line, Tumor Chemotherapy Cisplatin Cisplatin - administration & dosage Cytochrome c Cytotoxicity Deoxyribonucleic acid Diterpenes - administration & dosage DNA DNA damage DNA repair Drug dosages Drug Synergism Epoxy Compounds - administration & dosage Gastric cancer Hematology, Oncology and Palliative Medicine Herbal medicines Humans Male Membrane potential Mice Mice, SCID Mitochondria Mortality Phenanthrenes - administration & dosage Phytotherapy - methods Plant Extracts Proliferating cell nuclear antigen Severe combined immunodeficiency Side effects Stomach Neoplasms - drug therapy Studies Therapeutic applications Toxicity Tripterygium triptolide Tumors Xenograft Model Antitumor Assays Xenografts |
Title | Synergistic anticancer activity of triptolide combined with cisplatin enhances apoptosis in gastric cancer in vitro and in vivo |
URI | https://www.clinicalkey.es/playcontent/1-s2.0-S0304383512000316 https://www.ncbi.nlm.nih.gov/pubmed/22306340 https://www.proquest.com/docview/1506076094 https://search.proquest.com/docview/1238105859 |
Volume | 319 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEF7cFEovpe-6TcsWejMKeqy01rGEBBPs9BAb3NOi1SN1SCRjSYb20P71zuxDEiSBtBdhjXZXsr5PszOrmREhX2Ti5V4ACLhMgoMii8yRGXgpKcz9nAc89lW1_cV5NFuxs3W4Ho3aYXZJI4_SX3fmlfwPqiADXDFL9h-Q7QYFAfwGfGELCMP2QRhf_MTMPVVqeQJ3CDVamu9UfYy9CbVoUClU15sMo9JvwA3uws039Rbj4MpJXv7AfvUk2VbQFiuUgPQywS96pBMzJkhgyF1lqjXBzr4aGrbHutm1yg7q7PT5Rr_S3yTOWWvmSP0JKiMvL53vbU8ts3gNDrKjdvrlfn1ggR1mdW6OmNUKDPuIbPa3ydLCNzFTXaLEauDAaM3NwBM2-tQNBlOzr9NWb2l9vQBxBR59CX8T4_V8VYvVvaPI9vk3cbqaz8XyZL18RB77PA7RZz_6PYgMYqo-c3epNuNShQXePsd9Fs19HouyXJbPyTPjctCvmj8vyCgvX5InCxNU8Yr8GdCI9jSilka0KmhPI2ppRJFGtKMRtTSiHY0oSA2NqBkTJIpGcJ5M7-yr12R1erI8njnmuxxOCsZ3Aw8zz-OURWEa-i7OCEEhIz-NCh5GPJFxGrpRlskkCBPPzTjIQBmEvAB9D9MFTLFvyEFZlfk7Qv1iWvA4ARszYEzGLJbSj30vkZlkUzYNxsSx91ZsdfkVYeMSr4TGQiAWwvUEYDEm3AIgbGoxTIZ5bZ7aWniihsbiAtFFcD3MVQs86Hlo8RJ9Yyy_ySM3ZmPyuTsMChjfqiVlXrXQBo1eF7zueEzeapy7S_XRwQ-Y-_4BvT-Qp_0Dc0gOml2bfwSDt5GfFD3_AnvdruY |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Elsevier |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Synergistic+anticancer+activity+of+triptolide+combined+with+cisplatin+enhances+apoptosis+in+gastric+cancer+in+vitro+and+in+vivo&rft.jtitle=Cancer+letters&rft.au=Li%2C+Chia-Jung&rft.au=Chu%2C+Ching-Yu&rft.au=Huang%2C+Lin-Huang&rft.au=Wang%2C+Ming-Hseng&rft.date=2012-06-28&rft.issn=0304-3835&rft.volume=319&rft.issue=2&rft.spage=203&rft.epage=213&rft_id=info:doi/10.1016%2Fj.canlet.2012.01.006&rft.externalDBID=NO_FULL_TEXT |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F03043835%2FS0304383512X00089%2Fcov150h.gif |